North America was Maravai Lifesciences Holdings’s largest segment in fiscal 2025, bringing in $85.23M of $125.00M (68%).
| Segment | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| North America | $312.12M | $114.46M | $153.81M | $85.23M |
| Europe, The Middle East & Africa | $415.30M | $34.39M | $68.50M | $16.12M |
| Asia Pacific | $85.51M | $75.72M | $20.06M | $21.99M |
| Latin & Central America | $1.47M | $850.00K | $1.11M | $1.66M |
| Total | $814.40M | $225.42M | $243.48M | $125.00M |
Maravai Lifesciences Holdings brought in $125.00M from its four segments in fiscal 2025, the year ended December 31, 2025. That was down 48.7% from $243.48M in fiscal 2024. North America was the largest at $85.23M (68.2%), ahead of Asia Pacific at $21.99M (17.6%) and Europe, The Middle East & Africa at $16.12M (12.9%). The remaining segment, Latin & Central America, brought in $1.66M.
Compared with fiscal 2024, Asia Pacific grew fastest, up 9.6% to $21.99M, while Europe, The Middle East & Africa fell the most, down 76.5% to $16.12M. From fiscal 2022 to 2025, combined revenue from these segments fell from $814.40M to $125.00M, a compound annual decline of 46.5%. North America's share of the total rose from 38.3% to 68.2%.
Trilink was Maravai Lifesciences Holdings’s largest segment in fiscal 2025, bringing in $85.23M of $112.38M (76%).
| Statement Business Segments | FY 2019 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Nucleic Acid Production | $415.30M | — | — | — | |
| Trilink | — | $114.46M | $100.37M | $85.23M | |
| Cygnus | — | $26.60M | $26.72M | $27.15M | |
| Biologics Safety Testing | $27.35M | — | — | — | |
| Protein Detection | — | — | — | — | |
| Total | $442.65M | $141.06M | $127.09M | $112.38M |
Maravai Lifesciences Holdings brought in $112.38M from its two segments in fiscal 2025, the year ended December 31, 2025. That is less than the $125.00M it reports by segment, so these segments do not cover all of its revenue. Trilink was the largest at $85.23M (75.8%), ahead of Cygnus at $27.15M (24.2%).
Compared with fiscal 2024, Cygnus grew 1.6% to $27.15M, while Trilink fell 15.1% to $85.23M.
Maravai Lifesciences Holdings began breaking out Trilink in fiscal 2023 and Cygnus in fiscal 2023. Maravai Lifesciences Holdings stopped reporting Nucleic Acid Production ($415.30M in fiscal 2022) and Biologics Safety Testing ($27.35M in fiscal 2022) as separate segments.
As Reported was Maravai Lifesciences Holdings’s largest revenue line in fiscal 2024, bringing in $202.78M of $206.60M (98%).
| Revision of Prior Period | FY 2024 | FY 2024 |
|---|---|---|
| As Reported | $137.58M | $202.78M |
| Adjustments | -$3.98M | $3.83M |
| Total | $133.60M | $206.60M |
Maravai Lifesciences Holdings brought in $206.60M from its two revenue lines in fiscal 2024, the year ended September 30, 2024. That was up 54.6% from $133.60M in fiscal 2024. As Reported was the largest at $202.78M (98.1%), ahead of Adjustments at $3.83M (1.9%).
Maravai Lifesciences Holdings (MRVI) reports its revenue by segment, by statement business segments and by revision of prior period. In fiscal 2025, North America was its largest segment, bringing in $85.23M (68.2% of the total), followed by Asia Pacific at $21.99M (17.6%).
North America was Maravai Lifesciences Holdings' largest segment in fiscal 2025, bringing in $85.23M, or 68.2% of the $125.00M total across its four segments.
As Reported was Maravai Lifesciences Holdings' largest revenue line in fiscal 2024, bringing in $202.78M, or 98.1% of the $206.60M total across its two revenue lines.
Among Maravai Lifesciences Holdings' segments that make up at least 2% of revenue, Asia Pacific grew fastest in fiscal 2025, up 9.6% from $20.06M to $21.99M.
Every figure comes from Maravai Lifesciences Holdings' annual financial filings, as reported. Each line keeps the name Maravai Lifesciences Holdings gives it, and years follow its fiscal calendar.
Maravai Lifesciences Holdings' revenue by segment goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.